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Abstract
Background: The HMGA2 gene, coding for an architectural transcription factor involved in mesenchymal 
embryogenesis, is frequently deranged by translocation and/or amplification in mesenchymal tumours, generally 
leading to over-expression of shortened transcripts and a truncated protein.
Methods: To identify pathways that are affected by sarcoma-associated variants of HMGA2, we have over-expressed 
wild type and truncated HMGA2 protein in an immortalized mesenchymal stem-like cell (MSC) line, and investigated 
the localisation of these proteins and their effects on differentiation and gene expression patterns.
Results: Over-expression of both transgenes blocked adipogenic differentiation of these cells, and microarray analysis 
revealed clear changes in gene expression patterns, more pronounced for the truncated protein. Most of the genes 
that showed altered expression in the HMGA2-overexpressing cells fell into the group of NF-κB-target genes, 
suggesting a central role for HMGA2 in this pathway. Of particular interest was the pronounced up-regulation of SSX1, 
already implicated in mesenchymal oncogenesis and stem cell functions, only in cells expressing the truncated protein. 
Furthermore, over-expression of both HMGA2 forms was associated with a strong repression of the epithelial marker 
CD24, consistent with the reported low level of CD24 in cancer stem cells.
Conclusions: We conclude that the c-terminal part of HMGA2 has important functions at least in mesenchymal cells, 
and the changes in gene expression resulting from overexpressing a protein lacking this domain may add to the 
malignant potential of sarcomas.
Background
HMGA2 belongs to a family of nuclear proteins that con-
tain an N-terminal part that recognizes and binds to AT-
rich regions in the DNA [1] and an acidic C-terminal tail
that probably modulates their interactions with DNA [2],
and proteins [3]. HMGA proteins are not transactivators
on their own, but modulate the assembly of transcrip-
tional complexes at various levels [4-8], and may also reg-
ulate gene transcription through protein-protein
interactions without direct contact with DNA [9-11] or
by altering chromatin structure [12-16]. Interestingly, a
recent study suggested that both HMGA1 and HMGA2
are taking active parts in the formation of senescence-
associated heterochromatin foci and maintenance of the
growth-arrested state [17,18].
HMGA2 is expressed during embryonic development
while it is almost undetected in normal adult tissues
[19,20]. HMGA2 plays a critical role early in adipogene-
sis, probably by regulating the proliferation of preadipo-
cytes during differentiation [21], and mice lacking
functional HMGA2 protein exhibit a pygmy phenotype
with drastic reduction of adipose tissue [22]. On the other
hand, over-expression of a truncated HMGA2 protein
lacking the acidic C-terminal tail results in a giant pheno-
type with multiple lipomas [23,24].
Aberrations in the chromosomal region 12q14-15 that
affect HMGA2 are frequent in a variety of tumours. In
benign tumours of mesenchymal origin, HMGA2 is often
rearranged by translocation, and the resulting chimeric
transcripts are formed by fusion of the DNA-binding
domains, coded by exons 1-3, to ectopic sequences [25-
27]. In sarcomas, HMGA2 is frequently and selectively
amplified and rearranged [28]. We have cloned and
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sequenced a number of these cancer-associated ectopic
sequences from 12q as well as other chromosomes [29].
The only common factor that was found was the loss of
the 3'-untranslated region (UTR) as well as the last two
exons, resulting in fusion proteins containing as little as
one extra amino acid replacing the C-terminal part [29].
Recently it was shown that the HMGA2 3'-UTR con-
tains target sites for the let-7 miRNA, and thus the above
mentioned rearrangements lead to increased levels of
HMGA2 protein due to loss of miRNA-mediated repres-
sion [30,31]. Thus the attention has shifted from possible
oncogenic effects of loss of the acidic domain to effects of
increased expression, even of the wild type protein. Fur-
thermore, it turns out that the balance between let-7 and
HMGA2 governs the exit of cells from the undifferenti-
ated and self-renewing state, and HMGA2 is now thought
to be central in cancer in general [32-35]. Because
HMGA2 most frequently is rearranged in well-differenti-
ated liposarcomas, border-line tumours resembling adi-
pose tissue, most sarcoma cell lines, representing highly
malignant cancers with a different tissue type, would not
be appropriate to detect a phenotype when the gene is
over-expressed. We therefore chose an immature, stem-
like mesenchymal cell line with adipogenic potential to
investigate whether the wild type and truncated forms of
the protein activate the same pathways, by performing
gene expression analysis.
Methods
DNA constructs
The coding sequence and the part of the HMGA2 gene
encoding the DNA-binding domain (exon 1-3) were PCR-
amplified from pBluescript-HMGI-C [27] and cloned
into pEGFP-C3 (Clontech, Palo Alto, CA, USA) generat-
ing pEGFP-HMGA2WT  and pEGFP-HMGA2TRUNC,
respectively.
Cell culture and stable transfectants
The human mesenchymal stem cell line (hMSC) trans-
duced with human telomerase reverse transcriptase
(hTERT), hMSC-TERT20 cells [36,37] were transfected
with the HMGA2 constructs described above, using
Fugene (Roche Diagnostics, Basel, Switzerland) according
to the manufacturer's protocol. Stable clones were
selected with 400 μg/ml G418 (Gibco BRL, Gaithersburg,
MD, USA) and clones with strong GFP-fluorescence were
established using fluorescence activated cell sorting. Cells
were maintained in RPMI1640 (Gibco) supplemented
with 10% fetal bovine serum and 100 μg/ml G418.
Fluorescence microscopy
Transfected hMSC-TERT20 cells grown on coverslips
were fixed with 10% formalin solution (Sigma-Aldrich, St.
Louis, MO, USA), permabilized with 0.1% Triton X-100
in PBS and blocked with 5% FCS. Staining for HMGA2
and B23 (nucleophosmin - a marker for the nuclear
matrix)[38] was performed using rabbit-anti HMGA2
(Strategic Diagnostics Inc., Newark, DE, USA), and
mouse-anti B23 followed by DyLight549-conjugated don-
key anti-rabbit and DyLight649-conjugated donkey anti-
mouse antibodies (Jackson Immunoresearch Laborato-
ries, West Grove, PA, USA), respectively. The samples
were mounted in Prolong Gold antifade reagent with
DAPI (Invitrogen, Carlsbad, CA, USA). The fluorescence
was visualized using a Zeiss LSM 510 confocal micro-
scope and pictures were taken of thin single plane sec-
tions.
Differentiation assay
The hMSC-TERT20 cells as described above, were
seeded at 10 000 cells/cm2 in medium supplemented with
a cocktail of 0.5 mM methylisobutylxanthine (Sigma-
Aldrich, St. Louis, MO, USA ), 1 μM dexamethasone
(Decadron™, MSD, Haarlem, Nederland), 2 μM insulin
(Sigma-Aldrich) and 20 μM Rosiglitazone (GlaxoSmith-
Kline, Harlow, UK) for 14 days. To monitor the differenti-
ation process, cultures were stained with Oil Red O
(Serva, Heidelberg, Germany). The stained neutral lipids
were extracted and the absorbance at 490 nm measured.
The number of cells was estimated by using SRB protein
assay on the same cultures. Briefly, proteins were precipi-
tated with 10% trichloracetic acid (Merck, Darmstadt,
Germany) and assayed by staining with sulforhodamine B
(Sigma-Aldrich), extraction and measuring the dye absor-
bance at 540 nm [39].
Northern blot analysis and quantitative RT-PCR
Total RNA was isolated from sub-confluent growing cells
using Trizol reagent (Invitrogen) according to the manu-
facturer's instructions. For Northern blot analysis, the
samples of RNA (10 μg) were run on a 1% formaldehyde
agarose gel, blotted onto a positively charged nylon mem-
brane and hybridizations were performed as described
[40]. Probes were sequentially hybridized to the mem-
brane and signals from an 18S rRNA oligonucleotide
were used to correct for unequal sample loading.
For quantitative RT-PCR, 0.5 μg of RNA from each
sample was reverse transcribed using the High-Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer's instructions. The
resulting cDNAs were used for real-time PCR using Taq-
Man Gene Expression Assays (Applied BioSystem; Addi-
tional file 1 Table S1). Threshold cycle (Ct) values were
measured and the comparative Ct method [41] was used
to calculate the log2- fold difference in transcript level of
the over-expressing cell lines relative to the parental. See
Additional file 1 Table S1 for probes.Henriksen et al. BMC Cancer 2010, 10:329
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Western blot analysis
Cells were harvested and protein lysates were prepared by
sonicating cells resuspended in a nuclear lysis buffer of 50
mM Tris-HCl, pH 7.5, 0.1% SDS, 0.5 M NaCl, 1% NP-40,
1% DOC, 2 mM EDTA supplemented with protease
inhibitors (all from Sigma-Aldrich). 5 μg protein were
subjected to SDS-PAGE, transferred onto an Immobilon-
P membrane (Millipore, Billerica, MA, USA) and probed
with anti-HMGA2 (Santa Cruz Technologies, Santa
Cruz, CA, USA) and anti-tubulin (Santa Cruz). Second-
ary antibodies conjugated to horse radish peroxidase
(Dako, Glostrup, Denmark) were used according to the
manufacturer's instructions. Detection of antibody sig-
nals was performed with chemiluminescence using
SuperSignal West Dura Extended Duration Substrate
(Pierce, Rockford, IL, USA).
Microarray analysis
Total RNA was isolated from sub-confluent growing cells
using Trizol reagent according to the manufacturer's pro-
tocol and global expression analysis was performed on
HG-U133 Plus 2.0 oligonucleotide arrays (Affymetrix,
Santa Clara, CA, USA). Labelling, hybridisation and
scanning were performed at the Rikshospitalet University
of Oslo Microarray Core Facility http://microarray.rik-
shospitalet.no using standard conditions. As we aimed to
detect changes above the variation expected from differ-
ent sub-lines, i.e. above 3-fold, one array per sample was
sufficient (the technical variation between arrays being
much smaller).
Flow cytometry analysis of surface markers
To verify differential expression of CD24 and HLA-DR on
the cell surface, subconfluent growing cells were har-
vested, incubated with phycoerythrine-conjugated anti-
bodies and rinsed several times in PBS. IFNγ-treated cells
were cultured with 100 U/ml INFγ (Sigma) for 40 hours
prior to antibody staining. Antibody staining was
detected with a triple-focus DIVA flow cytometer (Bec-
ton Dickinson, Franklin Lakes, NJ, USA). Antibodies
used; anti-HLA-DR (Becton Dickinson); anti-CD24
(Beckman-Coulter, Fullerton, CA, USA). Data were ana-
lyzed with FlowJo software (Tree star, Ashland, Oregon,
USA).
Analysis of promoter sequences
Analysis of putative transcription factor binding sites was
performed using MatInspector http://www.genom-
atix.de/cgi-bin/matinspector/matinspector.pl and TESS
http://www.cbil.upenn.edu/tess/. The genomic DNA
sequences were retrieved from the Ensembl genome
browser http://www.ensembl.org/index.html covering
1500 base pairs of the 5' flanking regions (upstream from
the transcriptional start sites) and 500 base pairs down-
stream. A core similarity of at least 0.80 from MatInspec-
tor or TESS analysis was used as cut-off for potential
match to known transcription factor recognition
sequences.
Microarray data analysis
For GeneChip arrays, the raw intensity of individual sam-
ples was normalized using Bioconductor and the GC-
RMA algorithm http://www.bioconductor.org[42]. Nor-
malized gene expression levels for each transfected cell
line were compared with the parental cell line and probe
sets that exhibited less than 3-fold intensity change were
removed from further analysis. The remaining probe sets
were initially annotated according to entries in the
NetAffx database http://www.affymetrix.com. Using the
Database for Annotation, Visualization and Integrated
Discovery (DAVID located at http://apps1.niaid.nih.gov/
david[43], lists of differentially expressed genes, common
or specific for the samples, were analysed to identify
Gene Ontology (GO) terms that were significantly over-
represented using a modified Fisher Exact test (EASE-
score < 0.05). The redundancy in the annotations was
reduced by applying the clustering algorithm available in
DAVID using intermediate stringency and default set-
tings for the Kappa statistics.
Results
Exogenous HMGA2 is localized to the nucleus
T o  b e  a b l e  t o  m o n i t o r  l o c a l i z a t i o n  o f  t h e  p r o t e i n s,  a n
enhanced green fluorescence protein (eGFP) tag was
fused to the amino terminal end of both HMGA2 pro-
teins. Cells expressing eGFP-HMGA2WT  or eGFP-
HMGA2TRUNC accumulate the eGFP-tagged proteins in
the nuclei, especially in DAPI-dense and nucleolar
regions (Fig. 1a), whereas eGFP alone showed general flu-
orescence throughout the cell, with lower level in nucleoli
than in the rest of the nuclei (not shown). Noteworthy,
both endogenous and fusion proteins co-localized with
DAPI-dense heterochromatin but they were also present
in numerous discrete foci that did not stain well by DAPI.
Moreover, both fusion proteins appeared to be enriched
in the nucleoli, detected by immunostaining against the
nuclear matrix marker nucleophosmin/B23 [38]. Immu-
nostaining for HMGA2, on the other hand, gave a more
even fluorescence also covering the nucleoli for both
endogeneous and ectopic HMGA2, and it is unclear
whether this indicates that the apparent nucleolar enrich-
ment of eGFP fusion proteins was a result of overexpres-
sion, or reduced nucleolar immunostaining could be due
to incomplete penetrance of antibodies into the nucleoli
compared to the efficient fluorescence from the fluores-
cent eGFP tags. Interestingly, endogenous HMGA2
seemed to be distributed throughout the granular region
in the nucleolus whereas the granular nucleophosmin/
B23 was restricted to the periphery. In addition, theHenriksen et al. BMC Cancer 2010, 10:329
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Figure 1 Characterization of hMSC-TERT20 cells stably over-expressing eGFP-HMGA2WT and eGFP-HMGA2TRUNC. a) Nuclear localization of 
eGFP-tagged HMGA2 proteins was observed in hMSC-TERT20 over-expressing eGFP-HMGA2WT or eGFP-HMGA2TRUNC. Endogenous HMGA2 was visu-
alized by immunofluorescent staining with an anti-HMGA2 antibody (The intensity in parental cells was adjusted to make observation of nucleolar 
fluorescence possible). The nucleolus was detected with an anti-B23 antibody, while heterochromatin was stained by DAPI, showing co-localization 
of HMGA2 with both nucleoli and heterochromatin. Arrowheads show concentration of endogenous or eGFP-tagged HMGA2 at sites that correspond 
with nucleoli, while an arrow indicates discrete foci of HMGA2 within nucleoli. b) Expression levels of endogenous and exogenous HMGA2 transcripts; 
expected size of the endogenous transcript is 4468 bp, while the exogenous is only 327 bp due to the lack of the 3' UTR. Top panel, northern blot of 
HMGA2 mRNAs. Lower panel, quantitation of total HMGA2 mRNA levels by real-time PCR, normalized for TBP expression and represented as fold in-
duction over parental cells. c) Expression levels of endogenous and exogenous HMGA2 proteins, as detected on western blot. d) Accumulation of fat 
in cell cultures grown in basal medium supplemented with MDI and Rosiglitazone for 14 days. e) Relative accumulation of fat-bound Oil Red O after 
14 days of differentiation of hMSC-TERT20 cells. Data from two independent experiments are shown. Par, Parental cells; eGFP, eGFP-transduced; WT, 
transduced with eGFP-HMGA2WT; Trunc, transduced with eGFP-HMGA2TRUNC f) Expression of CD24 and HLA-DRA on each hMSC TERT20-derived cell 
lines as measured by flow cytometric mean fluorescence intensity (MFI).Henriksen et al. BMC Cancer 2010, 10:329
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fusion proteins stayed bound to the condensed chromo-
somes during mitosis (data not shown).
The endogenous HMGA2 transcript and protein was
readily detected in hMSC-TERT20 cells (Fig. 1b and 1c),
and the ectopic transcript showed a lower steady-state
level than the endogenous transcript, as less than two-
fold increase of HMGA2 transcripts was measured by
quantitative PCR in the over-expressing cell lines. How-
ever, the levels of ectopically expressed protein was
increased several fold relative to endogenous HMGA2.
HMGA2 abolishes differentiation into the adipocytic 
lineage
Compared to the parental cells, forced expression of full-
length or truncated HMGA2 abolished the ability of the
cells to differentiate towards adipocytes and accumulate
fat (Fig. 1d). Noteworthy, the growth of the HMGA2-
overexpressing cells was unaffected by addition of differ-
entiation medium, whereas the proliferation of the paren-
tal cells was inhibited when differentiation was induced.
A control cell line expressing eGFP only showed growth
and differentiation patterns similar to the parental line
(i.e. within the variation expected when different pas-
sages of these cells was used, Fig 1d). The proliferation of
the different transfectants was indistinguish¬able from
that of the parental cells in the absence of differentiation
(not shown).
Identification of transcriptional targets
To find out how HMGA2 affects transcription, and possi-
ble effects of truncation, we analyzed the gene expression
profiles of proliferating cultures of the over-expressing
and the parental cell lines using the HG-U133 Plus 2.0
Affymetrix GeneChips. We identified 408 transcripts
that were up-regulated more than 3-fold relative to the
recipient cells in either of the two HMGA2-expressing
lines, while 477 transcripts were down-regulated more
than 3-fold. The microarray data were deposited in the
Array Express public database http://www.ebi.ac.uk/
microarray-as/ae/, accession number E-MEXP-2647),
and a list of the most differentially expressed genes is
shown in Table 1 (the complete list of transcripts changed
more than 3-fold is given in Additional file 2 Table S2).
Although the microarray technique can be used to detect
much smaller changes, we chose 3-fold as a level where
we would avoid smaller differences due to the prolonged
separate culturing of each transfectant line.
Interestingly, although both protein variants similarly
affected many genes, a large number of genes were differ-
ently affected. Out of 408 genes that showed up-regula-
tion, 66 genes were up regulated by both full-length and
truncated HMGA2. In addition, 84 and 258 were up-reg-
ulated in the cells expressing full-length and truncated
HMGA2 respectively. On the other hand, 139 genes were
down-regulated by both proteins while 99 and 239 were
down-regulated by full-length and truncated HMGA2
respectively. As the cells were analysed in their undiffer-
entiated state, we could not monitor genes directly
involved in differentiation. Although we detected no
change of the known HMGA2 target Imp2 (IGF2BP2)
[44] in this system, the about 2-fold down regulation by
both protein variants of both PPARα and PPARγ, central
regulators of adipogenesis, could contribute to the differ-
entiation block. In near all cases quantitative real-time
PCR (qPCR) analyses confirmed the direction of changes
in transcript levels observed by microarrays (Table 1). An
exception was members of the SSX gene family, which
were poorly distinguished by the microarray probes, and
of which only SSX1 was confirmed by real-time PCR.
Discrepant results were also found for LCP1, FGF1 and
H D A C 9 ,  w h i c h  m o s t  l i k e l y  w e r e  c a u s e d  b y  a l t e r n a t i v e
splicing according to entries in the Alternative Splicing
and Transcript Diversity database http://www.ebi.ac.uk/
astd/main.html.
The over all correlation between microarray and real-
time ratios between HMGA2 transfectants and parental
cells was 0,96. The cells transfected with eGFP only were
included in the real-time validation as indicated in Table
1, and although there were some discrepancies, the over
all correlation between real-time ratios relative to the
eGFP-transfectants and those for the parental cells was
0.94, indicating their high degree of similarity.
Transcriptional effects common to wild type and truncated 
HMGA2
Sixty-six genes were up- and 139 genes were down-regu-
lated by both proteins. A large fraction of the affected
genes are known direct targets for NF-κB, and potential
intrinsic binding sites for HMGA proteins could be found
within many of the NF-κB sites (Additional file 3 Table
S3). Most of these genes code for proteins involved in
cytokine signalling. All of the genes in the CXC
chemokine cluster in chromosome band 4q13.3 that were
expressed in the parental cell line were down-regulated
by both protein variants. Other cytokines that were ini-
tially expressed in the parental cells and down-regulated
upon HMGA2 expression were IL1B, IL1RN, IL6, IL11,
IL15 and LIF1, all containing validated or predicted NF-
κB sites and only IL11  and IL15 lack intrinsic binding
sites for HMGA proteins. Several other possible NF-κB
targets were down regulated by the over-expression of
either form of HMGA2, e.g. THBS2,  S100A4,  IFI44L,
SOD2, PSMB9, IGFBP1, SERPINB1, NFKBIA, BDKRB1
and PTGES, all associated with increased NF-κB activity
(http://people.bu.edu/gilmore/nf-kb/target/index.html
and references therein). We also observed a four-fold
decrease of the primary microRNA miR-146A
(MIRN146A), which is known to be regulated by NF-κBH
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Table 1: Identification of genes most differentially expressed between the parental cell line and the over-expressing cell lines
Changes in HMGA2WTcells Changes in HMGA2trunc cells
Rank Gene Description MA qPCR Rel. to 
EGFP*
Gene Description MA qPCR Rel. to 
EGFP*
a) 1 CXCL6 Chemokine (C-X-C motif) ligand 6 -8.4 -6.7 -2.2 CXCL6 Chemokine (C-X-C motif) ligand 6 -9.0 -6.3 -2.2
2 IL8 Interleukin 8 -7.5 -7.1 -6.4 HLA-DRA Major histocompatibility complex class II 
antigen DRA
-8.7 -8.1 -7.2
3 CD24 CD24 molecule -7.1 HLA-DPA1 Major histocompatibility complex class II 
antigen DPA1
-8.0 -6.8 -5.5
4 C13orf33 Chromosome 13 open reading frame 33 -6.5 ChGn Chondroitin beta-1,4-N-
acetylgalactosaminyltransferase
-6.5
5 PTGES Prostaglandin E synthase -6.3 PKIB cAMP-dependent protein kinase inhibitor 2 -6,4 -4.9 -5.0
6 ChGn Chondroitin beta-1,4-N-
acetylgalactosaminyltransferase
-5.6 IFI44L Interferon-induced protein 44-like -6.2
7 IL6 Interleukin 6 -5.5 LAMA4 Laminin alpha chain -6.2
8 PDE4D cAMP-specific phosphodiesterase 4D -5.2 SLC38A5 Solute carrier family 38, member 5 -6.0
9 IL1RN Interleukin 1 receptor antagonist -5.1 -4.4 -3.0 PTPRN2 Protein tyrosine phosphatise, receptor type, N2 -5.5
10 CES1 Carboxylesterase 1 -5.1 C13orf33 Chromosome 13 open reading frame 33 -5.4
11 KIAA1644 KIAA1644 protein -5.0 -3.4 -1.7 n/a Similar to Wnt-1 inducible signalling pathway 
protein 1
-5.4
12 SAMSN1 SH3-SAM adaptor protein -4.8 IL1B Interleukin1 beta -5.3 -4.3 -2.2
13 SERPIND1 Serpin peptidase inhibitor, clade D, member 
1
-4.7 F2RL1 Coagulation factor II receptor-like 1 -5.2
14 FAM5C Familiy with sequence similarity 5,member 
C
-4.4 CD74 CD74 antigen-associated invariant chain -5.2 -5.4 -4.3
15 n/a Transcribed sequence FLJ 26764 -4.3 IL1RN Interleukin 1 receptor antagonist -5.2 -5.2 -3.8
b) 1 ZBED2 Zinc finger BED domain-containing protein 
2
5.3 4.5 n/a transcribed sequence FLJ33010 6.7
2 SHROOM2 Shroom family member 2 4.6 CXCL12 Chemokine (C-X-C motif) ligand 12 6.4 2.7 2.0
3 FGF13 Fibroblast growth factor 13 4.5 4.6 5.6 PRSS7 Serine protease 7 6.0
4 BAI3 Brain-specific angiogenesis inhibitor 3 4.5 4.4 5.4 SULT1B1 Sulfotransferase 1B1 5.8
5 PLXNA4 Plexin A4 4.4 SSX1 Synovial sarcoma, X breakpoint 1 4.9 9.6 10.2
6 LCP1 Lymphocyte cytosolic protein 1 4.1 3.9 2.1 MMP3 Matrix metalloproteinase-3 4.7H
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4
7 C20orf197 Chromosome 20 open reading frame 197 4.0 CYB5R2 Cytochrome b5 reductase 2 4.5
8 G0S2 G0/S switch 2 3.7 5.6 5.4 KISS1 KiSS-1 metastasis-supressor 4.5
9 HDAC9 Histone deacetylase 9 3.7 1.5 EDN1 Endothelin 1 4.5
10 SIGLEC15 Sialic acid binding Ig-like lectin 15 3.7 SYNE1 Synaptic nuclear envelope protein 1 4.4
11 HCLS1 Hematopoietic cell-specific Lyn substrate 1 3.6 2.5 3.6 HAPLN1 Hyaluronan and proteoglycan link protein 1 4.4
12 LOC646340 similar to Ankyrin repeat domain-containing 
protein 18A
3.6 n/a transcribed sequence FLJ35091 4.4
13 GATA3 GATA binding protein 3 3.5 3.6 >10 n/a Similar to TATA box-binding protein-associated 
factor 1B
4.3
14 SH3BGRL2 SH3 domain binding glutamic acid-rich 
protein like 2
3.5 BAI3 Brain-specific angiogenesis inhibitor 3 4.2 4.6 5.6
15 PDE4B cAMP-specific phospodiesterase 4B 3.5 n/a Similar to cytochrome c oxidase I 4.1
The 15 most down- (a) and up-(b) regulated genes were ranked according to the expression fold change between transfectants and parental cells based on the microarray data. Changes in gene 
expression were validated by real time PCR using TaqMan assays, values in brackets are relative to those for the eGFP controls, for comparison. The expression level of each target gene was 
normalized for TBP expression and represented as fold induction over parental cells. Fold change ratios from both microarray (MA) and real-time assay (qPCR), including qPCR values (marked by 
an asterisk) calculated relative to those from eGFP only control cells, are shown.
Table 1: Identification of genes most differentially expressed between the parental cell line and the over-expressing cell lines (Continued)Henriksen et al. BMC Cancer 2010, 10:329
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[45]. Noteworthy, a less stringent criterion (>2-fold)
showed down-regulation of several other potential NF-κB
target genes, such as BCL2A1,  JUNB,  LGALS3,  HAS1,
TWIST1, PTGS2, CFLAR and BIC (encoding miR-155).
However, EDN1, MDK and TGM2, three genes thought
to be positively regulated by NF-κB [46-48], were strongly
up-regulated in both cell lines.
In addition, several putative interferon-responsive
genes were down-regulated, such as IFI27,  IFITM1,
ISGF3G, AIM2, KYNU, C1S and OASL. Since the regula-
tory region of both IFI27  and  IFITM1  contain IFN-α
s t i m u l a t e d  r e s p o n s e  e l e m e n t  ( I S R E ;  A d d i t i o n a l  f i l e  4
Table S4) that are recognized by the ISGF3 complex [49]
t h e y  w o r k  d o w n s t r e a m  o f  I S G F 3 G  a n d  a r e  t h e r e f o r e
strongly dependent on the expression of the ISGF3G
gene. The ISGF3G gene itself is known to be regulated by
IL-6 [50] which indicates that these genes are secondary
targets to HMGA2.
Another large group of genes that showed expression
change was the Krüppel-type zinc finger proteins located
in several gene clusters mainly on the long arm of chro-
mosome 19 [51,52]. Some of these zinc finger proteins
contain a potent repressor domain, the Krüppel-associ-
ated box (KRAB), and they are likely involved in gene
silencing [53]. Interestingly, there was a broader up-regu-
lation of several other genes mapped to the chromosome
band 19q13 in the cell line over-expressing the truncated
HMGA2, including 35 Krüppel-type zinc finger genes of
which 27 contain a KRAB domain. This might indicate a
common regulatory mechanism for these genes that
could involve modulation of chromatin since there was
also an increased expression of several unrelated genes
near these clusters. Cells expressing HMGA2WT had an
increased expression of 12 Krüppel-type zinc finger
genes, nine of which mapped to the long arm of chromo-
some 19 and were up-regulated also in HMGA2TRUNC
transfectants. Six of the common up-regulated genes that
mapped to 19q contain a KRAB repressor domain, while
the three genes mapped to other chromosome regions,
showing elevated expression only in the cells expressing
HMGA2WT, all contain KRAB domains.
A gene ontology (GO) analysis revealed a highly signifi-
cant decrease in expression of genes encoding proteins
involved in signal transduction (p < 0.001) and response
to wounding (p < 0.001), mainly affecting genes involved
in cytokine-receptor signalling (p < 0.001), chemotaxis (p
< 0.001) and inflammatory response (p < 0.001). In addi-
tion, down-regulation of genes involved in regulation of
cellular proliferation (p = 0.0033) and epithelial cell dif-
ferentiation (p = 0.026) was observed. A few genes
involved in vascular development (p = 0.033) were up-
regulated. However, six out of 66 up-regulated genes
encode Krüppel-type zinc finger proteins containing a
KRAB repressor domain (p = 0.0051), indicating a com-
mon regulatory mechanism for these genes (Table 2).
Reciprocal effects of different forms of HMGA2
There were several genes up-regulated by HMGA2WT
and down- regulated in cells expressing the truncated
form, such as FGF13,  EHF,  HCLS1,  MEST,  G0S2  and
PTPRN2. Two of the gene products, G0S2 and MEST, are
both implicated in adipogenesis [54-56] while FGF13,
EHF,  HCLS1  and  PTPRN2  are potential regulators of
stem cell activity [57] , senescence [58], adhesion [59] and
insulin secretion [60], respectively.
Transcriptional effects specific to full-length HMGA2
Eighty-four genes were up-regulated and 99 genes were
down-regulated more than three-fold by wild-type but
not truncated HMGA2. Most genes were classified into
groups of more general GO terms providing limited
information about the underlying processes affected by
full-length HMGA2. However, a significant number of
the up-regulated genes are cell-type-specific genes
involved in embryonal development and likely reflect a
transition in the differentiation state of the cells. Some of
the down-regulated genes affect gene transcription.
However, most of the affected genes were poorly anno-
tated and gave little information about their cellular func-
tion.
Transcriptional effects specific to truncated HMGA2
Two hundred and fifty-eight genes were up-regulated and
239 genes were down-regulated in the cells expressing the
truncated protein. HMGA2TRUNC  cells showed a clear
increase in expression of CXCL12  whereas the large
MHC class II gene cluster was down-regulated (Table
b1b). The down-regulation of the MHC class II gene
HLA-DRA was verified by qPCR (Table b1b) and using
flow cytometry, we could show that HLA-DRA was
expressed at a basal level on the surface of both the
parental cells and the cells over-expressing the wild type
HMGA2, but was strongly down-regulated in
HMGA2TRUNC cells in according with the expression data
(Fig. 1f). Adding interferon γincreased the expression of
HLA-DRA, resulting in a 40-fold increase in the level on
the HMGA2TRUNC cells, to give a level of surface protein
similar to that on the parental line (not shown).
Based on the microarray data, the SSX gene family
appeared to be co-induced in cells expressing
HMGA2TRUNC, but real-time PCR was only able to verify
the induction of SSX1 transcripts. Interesting, the expres-
sion increased by 1000-fold indicating a specific activa-
tion of this gene.
The GO analysis revealed a significant down-regulation
of genes involved in antigen presentation and processing
(p < 0.001), and organism development (p = 0.0021). AHenriksen et al. BMC Cancer 2010, 10:329
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Table 2: Functional annotation analysis of differentially expressed genes
Biological processes affected by over-expression of wild type and truncated HMGA2
Vascular development (4 of 66 up-regulated genes) p = 0.039
Response to wounding (17 of 139 down-regulated genes) p < 0.001
Signal transduction (40/139) p < 0.001
Chemotaxis (11/139) p < 0.001
Cytosolic calcium ion homeostasis (5/139) p < 0.001
Phosphate transport (5/139) p = 0.0017
Regulation of cell proliferation (11/139) p = 0.0033
Cell migration (8/139) p = 0.0057
Cell recognition (3/139) p = 0.027
Epithelial cell differentiation (3/139) p = 0.026
Wound healing (4/139) p = 0.042
Biological processes affected by over-expression of wild type HMGA2
Multi-cellular organismal development (20 of 84 up-regulated genes) p = 0.0011
Response to hormone stimulus (4/84) p = 0.0034
Regulation of signal transduction (7/84) p = 0.022
Pyridine nucleotide biosynthetic process (3 of 99 down-regulated genes) p = 0.0017
Steroid hormone receptor activity (3/99) p = 0.0032
Negative regulation of transcription factor activity (3/99) p = 0.0034
Positive regulation of transcription (7/99) p = 0.0065
Response to external stimulus (8/99) p = 0.042
Biological processes affected by over-expression of truncated HMGA2
Regulation of transcription (61 of 258 up-regulated genes) p < 0.001
Intracellular protein transport across a membrane (6/258) p = 0.0032
Membrane organization and biogenesis (11/258) p = 0.011
Ras protein signaling transduction (9/258) p = 0.031
Regulation of cytoskeleton organization and biogenesis (4/258) p = 0.042
Antigen processing and presentation (10 of 239 down-regulated genes) p < 0.001
Multi-cellular organismal development (41/239) p = 0.0021
Cell adhesion (16/239) p = 0.019
Eye morphogenesis (3/239) p = 0.035
The genes were classified into biological processes using gene ontology terms. Each biological process was determined if it was significantly 
over- or underrepresented (p < 0.05) by comparing the observed frequency of genes to the expected frequency of genes on the Affymetrix 
GeneChip that cover 50 547 known genes. Significantly over- or under-represented processes were grouped and ranked according to the 
geometric mean of their p-values. A representative annotation term for each cluster, the number of genes associated with the term and its 
p-value was listed.Henriksen et al. BMC Cancer 2010, 10:329
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large proportion of the up-regulated genes encode pro-
teins with roles in regulation of transcription (p < 0.001)
and most of them were KRAB-zinc finger proteins. In
addition, genes encoding proteins involved in intracellu-
lar protein transport across membranes (p = 0.0032),
organization of cytoskeletal structures (p = 0.042) and
Ras signalling (p = 0.031), were significant up-regulated.
Discussion
The deregulation of expression caused by the absence of
the 3'-UTR in our transgenes, and thus loss of let-7--
mediated inhibition, resulted in abundant expression of
HMGA2 protein (Fig. 1c). The eGFP fusion proteins were
shown to localise in the nucleus just like the endogenous
protein. Their distribution to the nucleoli (Fig. 1a, arrow-
heads) was unexpected though HMGA2 has previously
been found to interact with the mainly nucleolar nucleo-
phosmin/B23 protein [61]. Furthermore, the localization
of endogenous HMGA2 in the nucleoli was clearly
restricted to numerous discrete foci (Fig. 1a, arrow). The
distribution of these sites was occasionally scattered
throughout the nucleolus or more often restricted to the
periphery of the nucleolar body were they seemingly co-
localized with B23. In this outer part of nucleolus the late
processing of rRNAs takes place before they assemble
into ribosomal subunits [62], suggesting that HMGA2
might be involved in these processes. However, this could
also be a result of B23 acting as a molecular chaperone
[63], sequestering HMGA2 to the nucleolus, as described
for IRF-1 [64], pRb [65] and TRF2 [66].
Both wild type and truncated HMGA2 abrogated
growth inhibition and adipogenesis (Fig. 1d), probably by
a common mechanism. It appears that both HMGA2 pro-
teins prevented the growth arrest necessary for adipo-
genic differentiation, as cellular protein accumulated at
the same rate as in un-induced cells. Interestingly, a
recent study showed that the level of HMGA2 is highly
regulated during adipogenesis by let-7 and knockdown of
HMGA2 by this miRNA inhibited both clonal expansion
and the transition to terminal differentiation [67].
HMGA2 seems to act in a narrow window early in the
adipogenesis where it is involved in expanding the popu-
lation of preadipocytes and keeps the cells in an undiffer-
entiated state. This would be consistent with our HMGA2
over-expressing keeping the mesenchymal stem-like cells
in a proliferative state, preventing differentiation into adi-
pocytes. Transgenic mice overexpressing truncated
HMGA2 gene, on the other hand, develop well differenti-
ated lipomas and abundant adipose tissue [24]. This dis-
crepancy is not surprising, as the conditions during
culture in vitro and development in vivo are very differ-
ent, among other things due to the micro¬environment.
Furthermore, the absence in hMSC- TERT20 cells of p16,
encoded by the INK4A/ARF  locus, and possibly other
oncogenic alterations in our model system [37] may be
expected to contribute to the results, although this block-
age of differentiation was confirmed in preliminary
experiments using another, non-tumourigenic telom-
erase-immortalised MSC line (Stabell et al, unpublished).
It has recently been reported that HMGA2 represses
transcription of INK4A/ARF [68] and suggested that this
might be mediated through JUNB, a transactivator of
INK4A/ARF  [69]. Consistent with previous findings
[3,68], both HMGA2 forms down-regulated the expres-
sion of NF-κB regulated genes in the cells, and in addition
to binding sites for NF-κB, many of the down-regulated
genes identified here, including JUNB, also contain
potential intrinsic binding sites for HMGA2 (Additional
file 3 Table S3). These findings suggest that HMGA2 may
repress JUNB by interfering with the NF-κB mediated
transactivation of this gene. However, since the INK4A/
ARF locus is deleted in our cell model, we were not able
t o  c o n f i r m  a n  e f f e c t  o n  t h i s  g e n e  b y  o v e r - e x p r e s s i n g
HMGA2. One might speculate that the higher number of
genes affected by the truncated protein could be due to a
regulatory or moderating function of the c-terminal
domain, but this remains to be investigated further.
In spite of abnormal dynamics of growth and differenti-
ation of our model system, we expect the transcription
response to HMGA2 overexpression to reflect authentic
regulatory functions in an immature mesenchymal con-
text, as these cells show differentiation properties similar
to primary mesenchymal stem-like cell cultures.
HMGA2 is known to participate in the formation of
heterochromatin in senescent cells [18] and we found
that both full-length and truncated HMGA2 proteins co-
localized extensively with DAPI-dense regions, probably
enriched in heterochromatin (Fig. 1a). The modulation of
chromatin by HMGA2 could also be responsible for the
coordinated induction of the chromosome 19 KRAB-
ZNF genes. Several members of this family modulate cell
growth and survival, and they are implicated in malignant
disorders [70], although the functions of most of them are
largely unknown. Noteworthy, a recently study showed
that Apak, encoded by the ZNF420 gene, repress p53-
mediated apoptosis [71] and it was suggested that various
KRAB-type zinc-finger proteins may modulate p53 activ-
ity. Although the level of ZNF420 transcript increased
more than two-fold in cells over-expressing HMGA2, no
effects on pro-apoptotic genes were observed (data not
shown).
Interestingly, our most up-regulated gene, SSX1,
encodes a protein that also is involved in chromatin mod-
ulation, and is already involved in sarcoma oncogenesis
[72]. Members of this gene family are seen expressed in
germ cells and mesenchymal stem cells, decrease upon
differentiation into adipocytes and osteocytes [73,74],
and are expressed in various tumor types [75]. SSX pro-Henriksen et al. BMC Cancer 2010, 10:329
http://www.biomedcentral.com/1471-2407/10/329
Page 11 of 14
teins co-localize with Polycomb group (PcG) proteins in
the nucleus and likely act through these chromatin regu-
lators to maintain repression of target genes [76,77]. This
could suggest that they play a key role in maintaining
mesenchymal cell stemness [78], and that increased SSX1
expression could reflect a cancer stem cell phenotype.
Although the SSX gene family is highly conserved, the
variable activation of SSX genes reported in malignant
cells [74] suggests gene-specific transcription control.
Their restricted expression pattern is mainly governed by
epigenetic silencing [79,80], which could be affected by
HMGA2TRUNC. An AT-rich region 1 kb upstream from
transcription start of SSX1 contains a likely binding site
for HMGA2 (-1076 TATTAATAT), although it remains to
be proven that it binds specifically to HMGA2TRUNC.
Recent findings suggest that both HMGA2 [81] and SSX
proteins [73,82] are taking part in the epithelial mesen-
chymal transition, where epithelial cells convert to motile
mesenchymal cells [83]. However, the significance of
these processes in already mesenchymal cells is unclear.
Interestingly, we observed a change in both cell lines to a
more restricted but still mesenchymal phenotype by the
repression of some epithelial markers, such as keratin 14
(KRT14) and the P selectin ligand CD24, and up-regula-
tion of mesenchymal-specific genes such as CD44, proba-
bly shifting from a multi-lineage potential [84] to a more
restricted but proliferative state. The down-regulation of
the NF-κB pathway might signify an undifferentiated
mesenchymal phenotype committed to adipogenic lin-
eage depending on further signalling cues.
The induction of CXCL12  gene expression by
HMGA2TRUNC is probably the cause of down-regulation
of HLA-DRA and other major histocompatibility com-
plex class II (MHC-II) proteins on the cell surface, due to
this cytokine's ability to repress the class II transactivator
[85]. The fact that interferon induced HLA-DRA protein
levels to a similar level in parental and HMGA2TRUNC
cells supports this interpretation. Loss of MHC-II expres-
sion in lymphomas correlates with poor survival [86], and
absence of HLA-DR expression is seen in other cancers
[87]. Their lost ability to present tumor antigens on their
cell surfaces may contribute to their escape from immu-
nosurveillance and therefore this might also provide a
selective advantage to sarcoma cells expressing truncated
HMGA2.
Since HMGA2 truncation and amplification is
observed initially in the development of well-differenti-
ated liposarcomas, borderline tumours of adipocytic dif-
ferentiation, and always in combination with
amplification of the p53-blocking MDM2, we do not
expect a very "malignant" phenotype when HMGA2 is
overexpressed on its own. On the other hand, a pheno-
type where adipogenesis is inhibited would be consistent
with a role in adipogenic tumours. When truncated
HMGA2 is overexpressed in transgenic mice, they
develop adipose hypertrophy, which indicates that adipo-
cytic differentiation is not completely blocked [24]. Like
our constructs, theirs lack the 3' UTR, thus preventing
down regulation of HMGA2 by let-7  as differentiation
progresses, and the most likely explanation for the dis-
crepancy is that the balance of proliferation and differen-
tiation over weeks or months in vivo is sufficiently
different for our short-term in vitro conditions, or there
are differences in how human and mouse cells are regu-
lated at this level. Although we get the same result in
another non-transformed hMSC line, this model is also
based on ectopic activation of telomerase, which could
affect the result[88,89].
To investigate these questions, we will determine the
activity of truncated HMGA2 in sarcoma cells by siRNA-
based knock-down in cells with the natural malignant
genetic background.
Conclusions
Our results show that over-expression of truncated
HMGA2 induces a more mesenchymal (stem-like) phe-
notype, characterized by resistance toward differentia-
tion, over-expression of SSX1, lost expression of certain
epithelial markers and strengthened expression of mes-
enchymal markers. We suggest that amplification and
truncation of HMGA2 in sarcoma provide the tumors
with a more stem-like phenotype.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JH participated in the planning of the experiments, performed all the transfec-
tions and experiments for array analysis, performed most of the array data anal-
ysis, and writing of the manuscript. MS performed the differentiation analysis
and participated in the writing of the manuscript. LAMZ conceived the study,
supervised the practical work, and participated in writing of the manuscript.
SAUL performed the confocal microscopy analyses and participated in the
writing of the manuscript. MK constructed and provided the mesenchymal
model system used, and critically read the manuscript. OM conceived the
study, supervised the practical work, and participated in the writing of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Marwa Jalal for having performed the FACS, Russell Castro for the 
analysis of surface markers, and Hanne S. Sorte and Ingrid Østensen for their 
assistance with the microarray analyses. Microarray analyses were supported 
Additional file 1 Additional Table S1 TaqMan primers for real-time 
PCR.
Additional file 2 Additional Table S2 The complete list of transcripts 
changed more than 3-fold.
Additional file 3 Additional Table S3 Predicted NF-κB recognition 
sequences in affected genes.
Additional file 4 Additional Table S4 Predicted STAT2 recognitions 
sequences in affected genes.Henriksen et al. BMC Cancer 2010, 10:329
http://www.biomedcentral.com/1471-2407/10/329
Page 12 of 14
by the FUGE Platform for Microarray Technology (Norwegian Microarray Con-
sortium, NMC, microarray.no), funded by the Norwegian Research Council, and 
this study was supported by The Norwegian Cancer Society.
Author Details
1CAST, Cancer Stem Cell Innovation Centre, Department of Tumor Biology, The 
Norwegian Radium Hospital, Oslo University Hospital, N-0027 Oslo, Norway, 
2Department of Molecular Bioscience, University of Oslo, Oslo, Norway and 
3Department of Endocrinology, University Hospital of Odense, Denmark & 
Stem Cell Unit, College of Medicine, King Saud University, Riyadh, KSA
References
1. Reeves R, Nissen M: The AT-DNA-binding domain of mammalian high 
mobility group I chromosomal proteins. A novel peptide motif for 
recognizing DNA structure.  J Biol Chem 1990, 265(15):8573-8582.
2. Nissen MS, Reeves R: Changes in superhelicity are introduced into 
closed circular DNA by binding of high mobility group protein I/Y.  J 
Biol Chem 1995, 270(9):4355-4360.
3. Noro B, Licheri B, Sgarra R, Rustighi A, Tessari MA, Chau KY, Ono SJ, 
Giancotti V, Manfioletti G: Molecular dissection of the architectural 
transcription factor HMGA2.  Biochemistry 2003, 42(15):4569-4577.
4. Chase MB, Haga SB, Hankins WD, Williams DM, Bi Z, Strovel JW, Obriecht C, 
Berg PE: Binding of HMG-I(Y) elicits structural changes in a silencer of 
the human beta-globin gene.  Am J Hematol 1999, 60(1):27-35.
5. Edelstein LC, Lagos L, Simmons M, Tirumalai H, Gelinas C: NF-kappa B-
dependent assembly of an enhanceosome-like complex on the 
promoter region of apoptosis inhibitor Bfl-1/A1.  Mol Cell Biol 2003, 
23(8):2749-2761.
6. Klein-Hessling S, Schneider G, Heinfling A, Chuvpilo S, Serfling E: HMG I(Y) 
interferes with the DNA binding of NF-AT factors and the induction of 
the interleukin 4 promoter in T cells.  Proc Natl Acad Sci USA 1996, 
93(26):15311-15316.
7. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick 
M, Nirodi C, Beauchamp D, Johnson KN, Richmond A: Mechanism and 
biological significance of constitutive expression of MGSA/GRO 
chemokines in malignant melanoma tumor progression.  J Leukoc Biol 
1997, 62(5):588-597.
8. Thanos D, Maniatis T: The high mobility group protein HMG I(Y) is 
required for NF-kappa B-dependent virus induction of the human IFN-
beta gene.  Cell 1992, 71(5):777-789.
9. Chin MT, Pellacani A, Wang H, Lin SS, Jain MK, Perrella MA, Lee ME: 
Enhancement of serum-response factor-dependent transcription and 
DNA binding by the architectural transcription factor HMG-I(Y).  J Biol 
Chem 1998, 273(16):9755-9760.
10. Fedele M, Pierantoni GM, Visone R, Fusco A: E2F1 activation is 
responsible for pituitary adenomas induced by HMGA2 gene 
overexpression.  Cell Div 2006, 1(17):.
11. Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, Caretti 
G, Imbriano C, Mantovani R, Del Sal G, et al.: Transcriptional activation of 
the cyclin A gene by the architectural transcription factor HMGA2.  Mol 
Cell Biol 2003, 23(24):9104-9116.
12. Bonnefoy E, Bandu MT, Doly J: Specific binding of high-mobility-group I 
(HMGI) protein and histone H1 to the upstream AT-rich region of the 
murine beta interferon promoter: HMGI protein acts as a potential 
antirepressor of the promoter.  Mol Cell Biol 1999, 19(4):2803-2816.
13. Li O, Vasudevan D, Davey CA, Droge P: High-level expression of DNA 
architectural factor HMGA2 and its association with nucleosomes in 
human embryonic stem cells.  Genesis 2006, 44(11):523-529.
14. Reeves R, Leonard WJ, Nissen MS: Binding of HMG-I(Y) imparts 
architectural specificity to a positioned nucleosome on the promoter 
of the human interleukin-2 receptor alpha gene.  Mol Cell Biol 2000, 
20(13):4666-4679.
15. Reeves R, Nissen MS: Interaction of high mobility group-I (Y) 
nonhistone proteins with nucleosome core particles.  J Biol Chem 1993, 
268(28):21137-21146.
16. Zhao K, Kas E, Gonzalez E, Laemmli UK: SAR-dependent mobilization of 
histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted 
chromatin.  Embo J 1993, 12(8):3237-3247.
17. Funayama R, Saito M, Tanobe H, Ishikawa F: Loss of linker histone H1 in 
cellular senescence.  J Cell Biol 2006, 175(6):869-880.
18. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP, 
Lowe SW: A novel role for high-mobility group a proteins in cellular 
senescence and heterochromatin formation.  Cell 2006, 126(3):503-514.
19. Chiappetta GAV, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, 
Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A: High level 
expression of the HMGI (Y) gene during embryonic development.  
Oncogene 1996, 13(11):2439-2446.
20. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J: 
HMGI-C expression patterns in human tissues. Implications for the 
genesis of frequent mesenchymal tumors.  Am J Pathol 1996, 
149(3):775-779.
21. Anand A, Chada K: In vivo modulation of Hmgic reduces obesity.  Nat 
Genet 2000, 24(4):377-380.
22. Zhou X, Benson KF, Ashar HR, Chada K: Mutation responsible for the 
mouse pygmy phenotype in the developmentally regulated factor 
HMGI-C.  Nature 1995, 376(6543):771-774.
23. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ: Transgenic mice 
expressing a truncated form of the high mobility group I-C protein 
develop adiposity and an abnormally high prevalence of lipomas.  J 
Biol Chem 2000, 275(19):14394-14400.
24. Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, 
Santoro M, Croce CM, Fusco A: The expression of a truncated HMGI-C 
gene induces gigantism associated with lipomatosis.  Cancer Res 1999, 
59(19):4793-4797.
25. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, 
Morton CC, Chada K: Disruption of the architectural factor HMGI-C: 
DNA-binding AT hook motifs fused in lipomas to distinct 
transcriptional regulatory domains.  Cell 1995, 82(1):57-65.
26. Kazmierczak B, Wanschura S, Rosigkeit J, Meyer-Bolte K, Uschinsky K, 
Haupt R, Schoenmakers EF, Bartnitzke S, Van de Ven WJ, Bullerdiek J: 
Molecular characterization of 12q14-15 rearrangements in three 
pulmonary chondroid hamartomas.  Cancer Res 1995, 55(12):2497-2499.
27. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, 
Van de Ven WJ: Recurrent rearrangements in the high mobility group 
protein gene HMGI-C, in benign mesenchymal tumourst.  Nat Genet 
1995, 10(4):436-444.
28. Berner JM, Meza-Zepeda L, Kools PF, Forus A, Schoenmakers E, Van de Ven 
WJ, Fodstad O, Myklebost O: HMGIC, the gene for an architectural 
transcription factor is amplified and rearranged in a subset of human 
sarcomas.  Oncogene 1997, 14(24):2935-2941.
29. Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, 
Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O: Ectopic 
sequences from truncated HMGIC in liposarcomas are derived from 
various amplified chromosomal regions.  Genes Chromosomes Cancer 
2001, 31(3):264-273.
30. Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the 
HMGA2 oncogene.  Genes Dev 2007, 21(9):1025-1030.
31. Mayr C, Hemann MT, Bartel DP: Disrupting the pairing between let-7 
and Hmga2 enhances oncogenic transformation.  Science 2007, 
315(5818):1576-1579.
32. Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer 
O: Expression of high-mobility-group-protein HMGI-C mRNA in the 
peripheral blood is an independent poor prognostic indicator for 
survival in metastatic breast cancer.  Br J Cancer 2003, 88(9):1406-1410.
33. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M: Clinical 
significance of high mobility group A2 in human gastric cancer and its 
relationship to let-7 microRNA family.  Clin Cancer Res 2008, 
14(8):2334-2340.
34. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, 
Lengyel E, Peter ME: Let-7 expression defines two differentiation stages 
of cancer.  Proc Natl Acad Sci USA 2007, 104(27):11400-11405.
35. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, 
Lieberman J, et al.: let-7 regulates self renewal and tumorigenicity of 
breast cancer cells.  Cell 2007, 131(6):1109-1123.
36. Simonsen J, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan S, 
Jensen T, Kassem M: Telomerase expression extends the proliferative 
life-span and maintains the osteogenic potential of human bone 
marrow stromal cells.  Nature Biotechnology 2002, 20(6):592-596.
Received: 15 January 2010 Accepted: 25 June 2010 
Published: 25 June 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/329 © 2010 Henriksen et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:329Henriksen et al. BMC Cancer 2010, 10:329
http://www.biomedcentral.com/1471-2407/10/329
Page 13 of 14
37. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, 
Kassem M: Adult human mesenchymal stem cell as a target for 
neoplastic transformation.  Oncogene 2004, 23(29):5095-5098.
38. De Angelis P, Stokke T, Clausen O: NO38 expression and nucleolar 
counts are correlated with cellular DNA content but not with 
proliferation parameters in colorectal carcinomas.  Mol Pathol 1997, 
50(4):201-208.
39. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren 
JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay 
for anticancer-drug screening.  J Natl Cancer Inst 1990, 82(13):1107-1112.
40. Forus A, Flørenes V, Maelandsmo G, Meltzer P, Fodstad O, Myklebost O: 
Mapping of amplification units in the q13-14 region of chromosome 
12 in human sarcomas: some amplica do not include MDM2.  Cell 
Growth Differ 1993, 4(12):1065-1070.
41. Schmittgen T, Livak K: Analyzing real-time PCR data by the comparative 
C(T) method.  Nat Protoc 2008, 3(6):1101-1108.
42. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, (eds): Bioinformatics 
and Computational Biology Solutions Using R and Bioconductor.  
Springer; 2005. 
43. Huang  DW, Sherman B, Lempicki R: Systematic and integrative analysis 
of large gene lists using DAVID bioinformatics resources.  Nature 
Protocols 2009, 4(1):44-57.
44. Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M, Sciot R, Van 
de Ven WJ, Petit MM: HMGA2 regulates transcription of the Imp2 gene 
via an intronic regulatory element in cooperation with nuclear factor-
kappaB.  Mol Cancer Res 2007, 5(4):363-372.
45. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent 
induction of microRNA miR-146, an inhibitor targeted to signaling 
proteins of innate immune responses.  Proc Natl Acad Sci USA 2006, 
103(33):12481-12486.
46. Kuncio GS, Tsyganskaya M, Zhu J, Liu SL, Nagy L, Thomazy V, Davies PJ, 
Zern MA: TNF-alpha modulates expression of the tissue 
transglutaminase gene in liver cells.  Am J Physiol 1998, 274(2 Pt 
1):G240-245.
47. Woods M, Wood EG, Bardswell SC, Bishop-Bailey D, Barker S, Wort SJ, 
Mitchell JA, Warner TD: Role for nuclear factor-kappaB and signal 
transducer and activator of transcription 1/interferon regulatory 
factor-1 in cytokine-induced endothelin-1 release in human vascular 
smooth muscle cells.  Mol Pharmacol 2003, 64(4):923-931.
48. You X, Wu Y, Zeng Y, Deng Z, Qiu H, Yu M: Mycoplasma genitalium-
derived lipid-associated membrane proteins induce activation of 
MAPKs NF-kappaB and AP-1 in THP-1 cells.  FEMS Immunol Med 
Microbiol 2008, 52(2):228-236.
49. Qureshi S, Salditt-Georgieff M, Darnell JJ: Tyrosine-phosphorylated Stat1 
and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-
stimulated-gene factor 3.  Proc Natl Acad Sci USA 1995, 92(9):3829-3833.
50. Weihua X, Hu J, Roy SK, Mannino SB, Kalvakolanu DV: Interleukin-6 
modulates interferon-regulated gene expression by inducing the 
ISGF3 gamma gene using CCAAT/enhancer binding protein-beta(C/
EBP-beta).  Biochim Biophys Acta 2000, 1492(1):163-171.
51. Tadepally HD, Burger G, Aubry M: Evolution of C2H2-zinc finger genes 
and subfamilies in mammals: species-specific duplication and loss of 
clusters genes and effector domains.  BMC Evol Biol 2008, 8(176):.
52. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, 
Yandell M, Evans CA, Holt RA, et al.: The sequence of the human genome.  
Science 2001, 291(5507):1304-1351.
53. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ, Rauscher FJ: 
Kruppel-associated boxes are potent transcriptional repression 
domains.  Proc Natl Acad Sci USA 3rd edition. 1994, 91(10):4509-4513.
54. Takahashi M, Kamei Y, Ezaki O: Mest/Peg1 imprinted gene enlarges 
adipocytes and is a marker of adipocyte size.  Am J Physiol Endocrinol 
Metab 2005, 288(1):E117-124.
55. Zandbergen F, Mandard S, Escher P, Tan N, Patsouris D, Jatkoe T, Rojas-
Caro S, Madore S, Wahli W, Tafuri S, et al.: The G0/G1 switch gene 2 is a 
novel PPAR target gene.  Biochem J 2005, 392(2):313-324. 2005 Dec 
1;392(Pt 2):313-24
56. Kamei ST Y, Kohda T, Ishino F, Yasuda K, Miura S, Ezaki O, Ogawa Y: Peg1/
Mest in obese adipose tissue is expressed from the paternal allele in an 
isoform-specific manner.  FEBS Lett 2007, 581(1):91-96.
57. Kawano M, Suzuki S, Suzuki M, Oki J, Imamura T: Bulge- and basal layer-
specific expression of fibroblast growth factor-13 (FHF-2) in mouse 
skin.  J Invest Dermatol 2004, 122(5):1084-1080.
58. Fujikawa M, Katagiri T, Tugores A, Nakamura Y, Ishikawa F: ESE-3, an Ets 
family transcription factor is up-regulated in cellular senescence.  
Cancer Sci 2007, 98(9):1468-1475.
59. Gomez T, McCarney S, Carrizosa E, Labno CM CE, Nolz JC, Zhu P, 
Freedman BD, Clark MR, Rawlings DJ, Billadeau DD, Burkhardt JK: HS1 
functions as an essential actin-regulatory adaptor protein at the 
immune synapse.  Immunity 2006, 24(6):741-752.
60. Doi A, Shono T, Nishi M, Furuta H, Sasaki H, Nanjo K: IA-2beta, but not IA-
2, is induced by ghrelin and inhibits glucose-stimulated insulin 
secretion.  Proc Natl Acad Sci USA 2006, 103(4):885-890.
61. Sgarra R, Tessari M, Di Bernardo J, Rustighi A, Zago P, Liberatori S, Armini A, 
Bini L, Giancotti V, Manfioletti G: Discovering high mobility group A 
molecular partners in tumour cells.  Proteomics 2005, 5(6):1494-1506.
62. Spector D: Macromolecular domains within the cell nucleus.  Annu Rev 
Cell Biol 1993, 9:265-315.
63. Szebeni A, Olson MO: Nucleolar protein B23 has molecular chaperone 
activities.  Protein Sci 8, 905-912 1999, 8(4):905-912.
64. Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, 
Tanaka N: Identification and characterization of nucleophosmin/B23/
numatrin which binds the anti-oncogenic transcription factor IRF-1 
and manifests oncogenic activity.  Oncogene 1997, 15(11):1275-1281.
65. Takemura M, Ohoka F, Perpelescu M, Ogawa M, Matsushita H, Takaba T, 
Akiyama T, Umekawa H, Furuichi Y, Cook P, et al.: Phosphorylation-
dependent migration of retinoblastoma protein into the nucleolus 
triggered by binding to nucleophosmin/B23.  Exp Cell Res 2002, 
276(2):233-241.
66. Zhang S, Hemmerich P, Grosse F: Nucleolar localization of the human 
telomeric repeat binding factor 2 (TRF2).  J Cell Sci 2004, 
117(17):3935-3945.
67. Sun T, Fu M, Bookout AL, Kliewer SA, Mangelsdorf DJ: MicroRNA let-7 
regulates 3T3-L1 adipogenesis.  Molecular endocrinology (Baltimore, Md 
2009, 23(6):925-931.
68. Nishino J, Kim I, Chada K, Morrison SJ: Hmga2 promotes neural stem cell 
self-renewal in young but not old mice by reducing p16Ink4a and 
p19Arf Expression.  Cell 2008, 135(2):227-239.
69. Passegué E, Wagner E: JunB suppresses cell proliferation by 
transcriptional activation of p16(INK4a) expression.  EMBO J 2000, 
19(12):2969-2979.
70. Tommerup N, Vissing H: Isolation and fine mapping of 16 novel human 
zinc finger-encoding cDNAs identify putative candidate genes for 
developmental and malignant disorders.  Genomics 1995, 
27(2):259-264.
71. Tian C, Xing G, Xie P, Lu K, Nie J, Wang J, Li L, Gao M, Zhang L, He F: KRAB-
type zinc-finger protein Apak specifically regulates p53-dependent 
apoptosis.  Nat Cell Biol 2009, 11(5):580-591.
72. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, Minami A, Hiraga 
H, Nishihara H, Sawa H, et al.: Analysis of transforming activity of human 
synovial sarcoma-associated chimeric protein SYT-SSX1 bound to 
chromatin remodeling factor hBRM/hSNF2 alpha.  Proc Natl Acad Sci 
USA 2001, 98(7):3843-3848.
73. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B: 
Cancer/testis antigen expression in human mesenchymal stem cells: 
down-regulation of SSX impairs cell migration and matrix 
metalloproteinase 2 expression.  Cancer Res 2005, 65(6):2207-2215.
74. Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, Knuth A, 
Pfreundschuh M, Old LJ, Chen YT: SSX: a multigene family with several 
members transcribed in normal testis and human cancer.  International 
journal of cancer 1997, 72(6):965-971.
75. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, Tsang S, Seitz G, 
Old LJ, Pfreundschuh M: Expression of SSX genes in human tumors.  Int J 
Cancer 1998, 77(1):19-23.
76. De Bruijn DR, van Dijk AH, Willemse MP, van Kessel AG: The C terminus of 
the synovial sarcoma-associated SSX proteins interacts with the LIM 
homeobox protein LHX4.  Oncogene 2008, 27(5):653-662.
77. Soulez M, Saurin AJ, Freemont PS, Knight JC: SSX and the synovial-
sarcoma-specific chimaeric protein SYT-SSX co-localize with the 
human Polycomb group complex.  Oncogene 1999, 18(17):2739-2746.
78. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K: Genome-wide 
mapping of Polycomb target genes unravels their roles in cell fate 
transitions.  Genes Dev 2006, 20(9):1123-1136.Henriksen et al. BMC Cancer 2010, 10:329
http://www.biomedcentral.com/1471-2407/10/329
Page 14 of 14
79. dos Santos N, de Bruijn D, van Kessel A: Molecular mechanisms 
underlying human synovial sarcoma development.  Genes 
Chromosomes Cancer 2001, 30(1):1-14.
80. de Bruijn D, dos Santos N, Kater-Baats E, Thijssen J, van den Berk L, Stap J, 
Balemans M, Schepens M, Merkx G, Van Kessel A: The cancer-related 
protein SSX2 interacts with the human homologue of a Ras-like 
GTPase interactor RAB3IP, and a novel nuclear protein SSX2IP.  Genes 
Chromosomes Cancer 2002, 34(3):285-298.
81. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin C, Moustakas A: 
Transforming growth factor-beta employs HMGA2 to elicit epithelial-
mesenchymal transition.  J Cell Biol 2006, 174(2):175-183.
82. Saito T, Nagai M, Ladanyi M: SYT-SSX1 and SYT-SSX2 interfere with 
repression of E-cadherin by snail and slug: a potential mechanism for 
aberrant mesenchymal to epithelial transition in human synovial 
sarcoma.  Cancer Res 2006, 66(14):6919-6927.
83. Hay E: The mesenchymal cell, its role in the embryo, and the 
remarkable signaling mechanisms that create it.  Dev Dyn 2005, 
233(3):706-720.
84. Abdallah B, Haack-Sørensen M, Burns J, Elsnab B, Jakob F, Hokland P, 
Kassem M: Maintenance of differentiation potential of human bone 
marrow mesenchymal stem cells immortalized by human telomerase 
reverse transcriptase gene despite [corrected] extensive proliferation.  
Biochem Biophys Res Commun 2005, 326(3):527-538.
85. Sheridan C, Sadaria M, Bhat-Nakshatri P, Goulet R Jr, Edenberg HJ, 
McCarthy BP, Chang CH, Srour EF, Nakshatri H: Negative regulation of 
MHC class II gene expression by CXCR4.  Exp Hematol 2006, 
34(8):1085-1092.
86. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, 
Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, et al.: Loss of 
MHC class II gene and protein expression in diffuse large B-cell 
lymphoma is related to decreased tumor immunosurveillance and 
poor patient survival regardless of other prognostic factors: a follow-
up study from the Leukemia and Lymphoma Molecular Profiling 
Project.  Blood 2004, 103(11):4251-4258.
87. Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, Suzuki H, Sasaki 
Y, Kanaseki T, Takamura Y, et al.: Epigenetic inactivation of class II 
transactivator (CIITA) is associated with the absence of interferon-
gamma-induced HLA-DR expression in colorectal and gastric cancer 
cells.  Oncogene 2004, 23(55):8876-8886.
88. Armstrong L, Saretzki G, Peters H, Wappler I, Evans J, Hole N, von Zglinicki 
T, Lako M: Overexpression of telomerase confers growth advantage, 
stress resistance, and enhanced differentiation of ESCs toward the 
hematopoietic lineage.  Stem Cells 2005, 23(4):516-529.
89. Yang C, Przyborski S, Cooke MJ, Zhang X, Stewart R, Anyfantis G, Atkinson 
SP, Saretzki G, Armstrong L, Lako M: A key role for telomerase reverse 
transcriptase unit in modulating human embryonic stem cell 
proliferation, cell cycle dynamics, and in vitro differentiation.  Stem Cells 
2008, 26(4):850-863.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/329/prepub
doi: 10.1186/1471-2407-10-329
Cite this article as: Henriksen et al., Identification of target genes for wild 
type and truncated HMGA2 in mesenchymal stem-like cells BMC Cancer 
2010, 10:329